View More Recent Stories
-
Hologic (HOLX) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 EPS Guidance
-
FDA Issues Alert on Hologic’s (HOLX) BioZorb Markers
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Hologic (HOLX) to Acquire Gynesonics
-
Hologic (HOLX) PT Raised to $90 at Mizuho
-
Citi Downgrades Hologic (HOLX) to Neutral
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Hologic (HOLX) authorizes new stock repurchase program
-
Citi Reiterates Buy Rating on Hologic (HOLX)
-
Hologic (HOLX) PT Raised to $95 at JPMorgan
-
Hologic (HOLX) Tops Q3 EPS by 4c, provides guidance
-
Hologic (HOLX) Completes Acquisition of Endomagnetics Ltd

